What's New on the FDA Drugs Site
September 26, 2013
- Current Drug Shortages Index (updated)
- FDA Drug Safety Podcast: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab)
- Drug Firm Annual Registration Status (updated)
- Drug Firm Annual Registration Status Download File (updated)
- National Drug Code Directory
New and Generic Drug Approvals
September 25, 2013
| Drug Name | Active Ingredient | Dosage Form/Route | Sponsor | Submission Type |
|---|---|---|---|---|
| Rebetol | ribavirin | Solution;Oral | Schering | Manufacturing Change or Addition |
| Vimpat | lacosamide | Tablet;Oral | Ucb Inc | Labeling Revision |
| Vimpat | lacosamide | Solution;Intravenous | Ucb Inc | Labeling Revision |
| Vimpat | lacosamide | Solution;Oral | Ucb Inc | Labeling Revision |
| This email was sent to kostikblog@ukr.net using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
